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A 72 year old female presented to the ER after she suffered a traumatic hip fracture following a dizzy spell.  She 
was trying to stand up when she suddenly became light headed and fell to the ground.  She denied any loss of 
consciousness, nausea, sweating or palpitations prior to the fall.  She recalls having had milder episodes similar 
to this over the prior few days, all developing when she tried to stand up. 
The patient has a history of coronary artery disease and severe ischemic cardiomyopathy.  Consequently, a car-
dioverter-defibrillator had been implanted.  Her functional class was estimated to be NYHA Class III at baseline.  
Current medications included aspirin, Carvedilol, lisinopril, spironolactone and furosemide; no recent change in 
her regimen had occurred. 
Physical examination revealed a BP 105/71, HR 109; orthostatic vitals were not obtained  due to the hip fracture.  
Jugular venous pressure was estimated to be 16 cm H2O and examination of the carotids revealed normal up-
stroke without bruits.  Auscultation of the lungs revealed bilateral crepitations.  The left lower extremity was 
mildly abducted and externally rotated; 2+ pitting edema was present bilaterally. 
Abnormal lab findings included Hemoglobin 8.2, serum glucose 217, BUN 28, Creatinine 1.4 and serum BNP of 
1500.  Imaging of the left hip demonstrated an oblique intertrochanteric fracture.  AP Chest film showed bilateral 
increased pulmonary markings with cephalization; a dual lead implantable cardiac device was noted.  An EKG 
revealed NSR without evidence of acute ischemia.  A 2D transthoracic echocardiogram demonstrated a mildly 
dilated left ventricle with an ejection fraction of 20% and an estimated RV systolic pressure of 45 mm Hg.  No 
valvular abnormalities were noted. 
 
Hospital Course:  At the time of admission, the patient was believed to be in decompensated heart failure (DHF).  
After discussion with the Orthopedic Team, it was decided to delay surgery until her cardiovascular condition 
was optimized.  She was treated with IV furosemide and her background heart failure therapy was continued; we 
held off on additional vasodilator therapy in light of her borderline hypotension. 
Though her presyncopal episode suggested postural hypotension, her AICD was interrogated to look for possible 
arrhythmias; none were found.  The patient responded well to the above therapy and was euvolemic by the third 
hospital day.  On day 5, she underwent intramedullary nail placement to repair the left intertrochanteric femur 
fracture; antitachyarrhythmia functions of the AICD were suspended intraoperatively.  She tolerated the surgery 
well and had no postoperative complications.  The patient was discharged to an inpatient rehabilitation center 
and was seen in the Orthopedic Clinic one month later; she was doing well and had started to ambulate. 
 
Discussion:  Heart Failure (HF) is a common condition that internists encounter during perioperative consulta-
tions.  HF is not only the most common postoperative cardiac complication but it is also considered to be a strong 
predictor of various other cardiovascular and pulmonary perioperative complications.  Although the focus of 
preoperative cardiac risk assessment is often on coronary artery disease (CAD), some studies suggest that under-
lying HF poses a higher risk for perioperative complications than does CAD.  For example, in one study of pa-
tients older than 65 undergoing major noncardiac surgery, the complication rate in HF patients was 11.7% com-
pared to 6.6% in CAD patients without HF [1].  We will discuss some of the questions raised during the manage-
ment of this patient. 
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Rise  Why delay non-emergent surgery in patients with decompensated heart failure?  How long should the opera-
tion be delayed? 
It is believed that the presence of DHF roughly doubles the risk of perioperative cardiac complications.  Current 
ACC/AHA guidelines consider DHF as a major predictor of increased perioperative risk of myocardial infarction, 
heart failure and cardiac death.  Accordingly, DHF requires intensive management which may delay or cancel 
non-emergent surgeries [2].  It is not clear how long the patient must be asymptomatic following treatment of 
their DHF in order to be considered “optimized” for surgery; studies on this topic are lacking but some experts 
suggest a period of one week, if possible.  The urgency and nature of the surgery must be taken into account 
when making decisions regarding the appropriate timing of the procedure. 
 
How do we manage DHF perioperatively? 
Diuretics, ACE inhibitors, ARBs, beta blockers and aldosterone antagonists constitute the primary pharmacother-
apy for DHF. 
Diuretics:  Patients with HF are usually maintained on loop diuretics to control the congestive features of the dis-
ease.  There is no consensus on whether or not these medications should be continued in the immediate peri-
operative period [3].  However, it is generally safe to continue these medications as long as proper attention is 
given to the patient’s volume status and electrolyte balance throughout the perioperative period.  Despite the 
paucity of evidence, the benefits of continuing diuretics seem to outweigh the risks in patients recovering from 
preoperative DHF. 
ACEIs and ARBs:  these medications are cornerstones in the management of heart failure but there is still contro-
versy regarding their perioperative use.  One study demonstrated that patients who took ACEIs through the 
morning of surgery were more likely to develop hypotension requiring vasopressors than did those who stopped 
their medication 12-24 hours prior to surgery [4].  Another study found that stopping ACEIs preoperatively 
caused significant postoperative hypertension [5].  It merits mention, however, that patients in the former study 
were on ACEIs for chronic hypertension  and it is not known how many of them had heart failure; in the latter 
study, the majority of patients had normal LV systolic function.  The decision whether  to continue these medica-
tions should be individualized, weighing the risk of intraoperative hypotension against the risk of postoperative 
hypertension.  Based on current available data, it seems appropriate to hold ACEs and ARBs in patients who 
have HF or hypotension preoperatively; on the other hand, it is likely best to continue them in patients who are 
normotensive or hypertensive preoperatively, thereby preventing postoperative hypertension and a secondary 
increase in afterload. 
Beta blockers (BB):  Patients with HF who are taking BB preoperatively should continue these medications on 
the morning of surgery.  Initiation of BB therapy in patients with HF requires slow titration and close monitoring 
since they might induce worsening of congestive symptoms.  Accordingly, perioperative initiation of BB is not 
recommended, especially in patients with DHF [2]. 
Aldosterone Antagonists:  Clinical trials have demonstrated that aldosterone antagonists reduce mortality in 
subsets of patients with systolic heart failure.  The benefit of these medications in heart failure is believed to be 
primarily through blocking the deleterious effect of aldosterone on the heart and by elevating serum potassium 
and thus decreasing the likelihood of hypokalemia facilitated arrhythmias.  Accordingly, in patients with normal 
serum potassium, it is expected that stopping or continuing these medications perioperatively is unlikely to affect 
the control of HF. 
 
(continued) 
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Rise  What is the role of Pulmonary Artery Catheters in monitoring patients with DHF during the perioperative 
period? 
PACs provide important and clinically relevant data in selected patients; however, their use involves an invasive 
procedure with increased risk of bleeding, infection and arrhythmias.  Earlier studies suggested that the use of a 
PAC was associated with increased mortality and length of stay in the hospital.  However, more recent studies 
demonstrated no difference in in-hospital mortality, 6 month mortality rate or postoperative heart failure when 
patients were randomized to perioperative management with or without a PAC [6,7].  The American Society of 
Anesthesiologists Task Force on Pulmonary Artery Catheterization concluded that, given the accumulating data 
showing benefits from PAC use, the decision to place a PAC should carefully weigh the potential risks and bene-
fits [8].  Current ACC/AHA guidelines support this approach and recommend against the routine use of PACs; 
these guidelines recommend considering PAC use in patients at high risk for hemodynamic disturbances that are 
best detected by such monitoring [2]. 
How do we deal with implantable cardiac rhythm management devices (CRMD) perioperatively? 
The potential for electromagnetic interference with an implanted device is related to the amount of current gener-
ated in the vicinity of the device (pacemaker or AICD).  Current produced by electrocautery can alter the function 
of the devices: e.g. resetting the backup pacing mode, temporary or permanent inhibition of pacemaker output, 
an increase in pacing rate due to activation of the rate-responsive sensor or induced firing of an AICD by the elec-
trical noise [2]. 
A task force on perioperative management of patients with CRMD by the American Society of Anesthesiology 
recommends the preoperative assessment of these patients should include: 1. determining the risk of electromag-
netic interference during the planned procedure, 2. determining whether reprogramming the CRMD pacemaking 
function to an asynchronous pacing mode or disabling any special algorithms is needed, 3. suspending antitachy-
arryhthmia functions if present, 4. advising the individual performing the procedure to consider use of a bipolar 
electrocautery system or ultrasonic (harmonic) scalpel to minimize potential adverse effects of electromagnetic 
interference on the pulse generator or leads and 5. assuring the availability of temporary pacing and defibrillation 
equipment.  The same task force recommends that, if electromagnetic interference is likely to occur, the conven-
tional pacing function of a CRMD be altered by changing to an asynchronous pacing mode in pacemaker de-
pendent patients and suspending special algorithms, including rate-adaptive functions.  These alterations may be 
accomplished by programming or by applying a magnet on the pacemaker.  However, the task force cautions 
against use of a magnet over an AICD since this may permanently disable the device; for this reason, the function 
of an AICD should be altered by programming[8]. 
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